Kidney Stone Inflammation
University of Chicago · NCT06436235
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–70 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- June 30, 2024
- Record last updated
- July 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This observational study aims to look at the connections between kidney stones, insulin resistance, and inflammation. The researchers hypothesize that people who form calcium kidney stones and have insulin resistance may have higher levels of inflammation because they have more visceral fat (fat around the abdominal organs).
The study will recruit 20 people who have had calcium kidney stones but don't have diabetes, and 20 healthy people who haven't had kidney stones. All the participants will come to the research center at the University of Chicago Medicine. Participants will have a dual-energy X-ray absorptiometry (DEXA) scan to measure their visceral fat, and give blood and urine samples. The blood will be tested for insulin resistance, inflammatory markers, and other metabolic factors. The urine will be analyzed for substances that increase kidney stone risk.
The main goal is to see if the kidney stone formers with insulin resistance have more visceral fat compared to those without insulin resistance and the healthy participants. The researchers will also compare inflammatory marker levels between groups, and look at how visceral fat, inflammatory markers, insulin resistance, and urine stone risk factors are related.
The findings may help explain how kidney stones are connected to metabolic conditions like diabetes and cardiovascular disease. Researchers hope this information will help identify stone formers at risk early and develop preventive treatments in the future.
Conditions: Kidney Stone; Stone, Kidney
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Stone formers:
- Age 18-70
- History of at least one calcium-based kidney stone
- Healthy Controls:
- Age 18-70
- No history of kidney stone or family history of kidney stones
Exclusion Criteria (for both groups):
- History of primarily uric acid
- Cysteine, or struvite stones
- History of diabetes or impaired glucose tolerance
- Previous thiazide use
- Anyone on a medication that cannot be stopped that may affect urine composition
- Previous bariatric surgery or ileostomy
- Primary hyperparathyroidism and elevated serum calcium.
Recruiting US locations
University of Chicago Medical Center
Chicago, IL 60637
Site contact: Megan Prochaska, MD · 773-702-1000 · mprocha2@medicine.bsd.uchicago.edu
Study contacts (from the official record)
- Megan Prochaska, MD · 773-702-1000 · mprocha2@medicine.bsd.uchicago.edu
- Elaine Worcester, MD · 773-702-3630 · eworcest@medicine.bsd.uchicago.edu
Similar studies in Illinois
All healthy volunteers studies in Illinois →- RecruitingHealthy volunteers
J-RISE: Relevant Implementation Strategies to Eliminate the Social and Structural Barriers to HIV Services Among Justice-involved Black Men Who Have Sex With Men and Other Key Populations
University of Chicago
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Melrose Park, IL + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
AbbVie
- Location
- Grayslake, IL + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers
AbbVie
- Location
- Grayslake, IL
- Eligibility basics
- Ages 18–65